Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 701-713 , December 2006

Novel antibody-based therapy for acute lymphoblastic leukaemia

  • Nicola Gökbuget, MD

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +49 69 6301 6365; Fax: +49 69 6301 7463.
  • Dieter Hoelzer, MD, PhD (Professor of Internal Medicine and Head of the Department)

References 

  1. Hoelzer D, Gökbuget N. Recent approaches in acute lymphoblastic leukemia in adults. Critical Reviews in Oncology/Hematology. 2000;36:49–58
  2. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. The New England Journal of Medicine. 2006;354:166–178
  3. Tallman MS. Monoclonal antibody therapies in leukemias. Seminars in Hematology. 2002;39:12–19
  4. Gökbuget N, Hoelzer D. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects. Annals of Hematology. 2003;83:201–205
  5. Chevallier P, Robillard N, Wuilleme-Toumi S, et al. Overexpression of Her-2/neu is observed in one third of adult B-ALL patients and is associated with chemoresistance in these patients. Blood. 2004;104:[Abstract #524]
  6. Maloney DG, Smith B, Rose A. Rituximab: mechanism of action and resistance. Seminars in Oncology. 2002;29:2–9
  7. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. The New England Journal of Medicine. 2002;346:235–242
  8. Avivi I, Robinson S, Goldstone A. Clinical use of rituximab in haematological malignancies. British Journal of Cancer. 2003;89:1389–1394
  9. Ozsahin H, Fluss J, Mclin V, et al. Rituximab with interleukin-2 after autologous bone marrow transplantation for acute lymphocytic leukemia in second remission. Medical and Pediatric Oncology. 2002;38:300–301
  10. Jandula BM, Nomdedeu J, Marin P, et al. Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia. Bone Marrow Transplantation. 2001;27:225–227
  11. De Vries MJ, Veerman AJ, Zwaan CM. Rituximab in three children with relapsed/refractory B-cell acute lymphoblastic leukaemia/Burkitt non-Hodgkin's lymphoma. British Journal of Haematology. 2004;125:414–415
  12. Corbacioglu S, Eber S, Gungor T, et al. Induction of long-term remission of a relapsed childhood B-acute lymphoblastic leukemia with rituximab chimeric anti-CD20 monoclonal antibody and autologous stem cell transplantation. Journal of Pediatric Hematology/Oncology. 2003;25:327–329
  13. Hoelzer D, Ludwig W-D, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996;87:495–508
  14. Hoelzer D, Arnold R, Diedrich H, et al. Successful treatment of Burkitt's NHL and other high-grade NHL according to a protocol for mature B-ALL. Blood. 2002;100:159a;[Abstract #595]
  15. Hoelzer D, Baur K-H, Giagounidis A, et al. Short intensive chemotherapy with rituximab seems successful in Burkitt NHL, mature B-ALL and other high-grade B-NHL. Blood. 2003;102:[Abstract #236]
  16. Hoelzer D, Gökbuget N, Beck J, et al. Subtype adjusted therapy improves outcome of elderly patients with acute lymphoblastic leukemia. Blood. 2004;104:[Abstract #2732]
  17. Thomas D, Faderl S, O'brien S, et al. Chemo-immunotherapy with hyper-CVAD plus ritixumab for adult Burkitt's and Burkitt's type lymphoma (BL) or acute lymphoblastic leukemia (B-ALL). Blood. 2005;106:[Abstract #149]
  18. Gökbuget N, De Wit M, Gerhardt A, et al. Results of a shortened, dose reduced treatment protocol in elderly patients with acute lymphoblastic leukemia (ALL) [abstract]. Blood. 2000;96:#3104
  19. Thomas D, Cortes J, O'brien C, et al. Update of the modified hyper-CVAD regimen with or without rituximab in newly diagnosed adult acute lymphocytic leukemia (ALL). Blood. 2005;106:[Abstract #1831]
  20. Seibel NL, Sather H, Steinherz PG, et al. Upfront treatment with B43 PAP immunotoxin in newly diagnosed children with higher risk ALL - Children's Cancer Group 1961. Blood. 2000;96:#3115
  21. Szatrowski TP, Dodge RK, Reynolds C, et al. Lineage specific treatment of adult patients with acute lymphoblastic leukemia in first remission with anti-B4-blocked ricin or high-dose cytarabine. Cancer. 2003;97:1471–1480
  22. Dinndorf P, Krailo M, Liu-Mares W, et al. Phase I trial of anti-B4-blocked ricin in pediatric patients with leukemia and lymphoma. Journal of Immunotherapy. 2001;24:511–516
  23. Uckun FM, Nachman JB, Sather HN, et al. Poor treatment outcome of Philadelphia chromosome-positive pediatric acute lymphoblastic leukemia despite intensive chemotherapy. Leukemia & Lymphoma. 1999;33:101–106
  24. Herrera L, Farah RA, Pellegrini VA, et al. Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia. 2000;14:853–858
  25. Herrera L, Yarbrough S, Ghetie V, et al. Treatment of SCID/human B cell precursor ALL with anti-CD19 and anti-CD22 immunotoxins. Leukemia. 2003;17:334–338
  26. Dijoseph JF, Armellino DC, Boghaert ER, et al. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004;103:1807–1814
  27. Lew G, Gu L, Zhou M, et al. BL22, an anti-CD22 recombinant immunotoxin, is active in vitro and in vivo against B-cell precursor acute lymlphoblastic leukemia (BCP-ALL) cells from pediatric patients. Blood. 2002;100:3024;[Abstract]
  28. Golay J, Cortiana C, Cazzaniga G, et al. Acute lymphoblastic leukemia cells carrying the t(12;21) translocation are highly sensitive to alemtuzumab mediated cell lysis. Blood. 2005;106:#872
  29. Kolitz JE, O'mara V, Willemze R, et al. Treatment of acute lymphoblastic leukemia (ALL) with Campath-1H: initial observations. Blood. 1994;84:#1191
  30. Piccaluga PP, Martinelli G, Malagola M, et al. Anti-leukemic and anti-GVHD effects of Campath-1H in acute lymphoblastic leukemia relapsed after stem-cell transplantation. Leukemia & Lymphoma. 2004;45:731–733
  31. Laporte JP, Isnard F, Garderet L, et al. Remission of adult acute lymphocytic leukaemia with alemtuzumab. Leukemia. 2004;18:1557–1558
  32. Faderl S, Kantarjian HM, O'brien S, et al. A broad exploratory trial of Campath-1H in the treatment of acute leukemias. Blood. 2000;96:1397a
  33. Stock W, Yu D, Sanford B, et al. Incorporation of alemtuzumab into front-line therapy of adult acute lymphoblastic leukemia (ALL) is feasible: a phase I/II study from the Cancer and Leukemia Group B (CALGB 10102). Blood. 2005;106:#145
  34. Massenkeil G, Rackwitz S, Genvresse I, et al. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation. Bone Marrow Transplantation. 2002;30:899–903
  35. Waldmann TA, White JD, Goldman CK, et al. The interleukin-2 receptor: a target for monoclonal antibody treatment of human T-cell lymphotrophic virus I-induced adult T-cell leukemia. Blood. 1993;82:1701–1712
  36. Zhang M, Zhang Z, Goldman CK, et al. Combination therapy for adult T-cell leukemia-xenografted mice: flavopiridol and anti-CD25 monoclonal antibody. Blood. 2005;105:1231–1236
  37. Tsimberidou AM, Giles FJ, Estey E, et al. The role of gemtuzumab ozogamicin in acute leukaemia therapy. British Journal of Haematology. 2006;132:398–409
  38. Mejstrikova E, Kalina T, Trka J, et al. Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy. Leukemia. 2005;19:1092–1094
  39. Golay J, Amico D, Cittera E, et al. Gemtuzumab ozogamicin (Mylotarg) has therapeutic activity against CD33 acute lymphoblastic leukaemias in vitro and in vivo. The Hematology Journal. 2005;Eha:#422
  40. Zwaan C, Reinhardt D, Jurgens H, et al. Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin. Leukemia. 2003;17:468–470
  41. Cotter M, Rooney S, O'marcaigh A, et al. Successful use of gemtuzumab ozogamicin in a child with relapsed CD33-positive acute lymphoblastic leukaemia. British Journal of Haematology. 2003;122:687–688
  42. Balduzzi A, Rossi V, Corral L, et al. Molecular remission induced by gemtuzumab ozogamicin associated with donor lymphocyte infusions in t(4;11) acute lymphoblastic leukemia relapsed after transplantation. Leukemia. 2003;17:2247–2248
  43. Frankel AE. New anti-T cell immunotoxins for the clinic. Leukemia Research. 2005;29:249–251
  44. Vallera DA, Burns LJ, Frankel AE, et al. Laboratory preparation of a deglycosylated ricin toxin a chain containing immunotoxin directed against a CD7 T lineage differentiation antigen for phase I human clinical studies involving T cell malignancies. Journal of Immunological Methods. 1996;197:69–83
  45. Frankel AE, Laver JH, Willingham MC, et al. Therapy of patients with T-cell lymphomas and leukemias using an anti-CD7 monoclonal antibody-ricin A chain immunotoxin. Leukemia & Lymphoma. 1997;26:287–298
  46. Waurzyniak BJ, Schneider EA, Tumer N, et al. In vivo toxicity, pharmacokinetics, and antileukemic activity of TXU (anti-CD7)-pokeweed antiviral protein immunotoxin. Clinical Cancer Research. 1997;3:881–890
  47. Zhang Z, Zhang M, Ravetch JV, et al. Effective therapy for a murine model of adult T-cell leukemia with the humanized anti-CD2 monoclonal antibody, MEDI-507. Blood. 2003;102(1):284–288
  48. Gramatzki M, Burger R, Strobel G, et al. Therapy with OKT3 monoclonal antibody in refractory T cell acute lymphoblastic leukemia induces interleukin-2 responsiveness. Leukemia. 1995;9:390
  49. Carpenter PA, Appelbaum FR, Corey L, et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood. 2002;99:2712–2719
  50. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood. 2003;101:391–398
  51. Kotzerke J, Bunjes D, Scheinberg DA. Radioimmunoconjugates in acute leukemia treatment: the future is radiant. Bone Marrow Transplantation. 2005;36:1021–1026
  52. Bunjes D, Duncker C, Seitz U, et al. Intensification of the conditioning regimen for high-risk leukaemia with a 188Re- labelled anti-CD 164b monoclonal antibody: results of feasibility study. Blood. 1998;92:4471a
  53. Bunjes D, Buchmann I, Duncker C, et al. Rhenium 188-labeled anti-CD66 (a, b, c, e) monoclonal antibody to intensify the conditioning regimen prior to stem cell transplantation for patients with high-risk acute myeloid leukemia or myelodysplastic syndrome: results of a phase I-II study. Blood. 2001;98:565–572
  54. Klein SA, Hermann S, Dietrich JW, et al. Transplantation-related toxicity and acute intestinal graft-versus-host disease after conditioning regimens intensified with Rhenium 188- labeled anti-CD66 monoclonal antibodies. Blood. 2002;99:2270–2271

PII: S1521-6926(06)00044-2

doi: 10.1016/j.beha.2006.06.008

Best Practice & Research Clinical Haematology
Volume 19, Issue 4 , Pages 701-713 , December 2006

Article Tools

* Image Usage & Resolution